用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达.docVIP

用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达 1 1 资料与方法 3 2 结果 5 文2：用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达 6 1 资料与方法 7 2 结果 9 3 讨论 11 参考文摘引言： 13 原创性声明（模板） 15 文章致谢（模板） 15 正文 用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达 文1：用DAKOHercepTest检测肝细胞癌HER2neu蛋白的表达 Expression of HER-2eu protein in hepatocellular carcinoma 【Abstract】 Objective To investigate HER-2eu protein overexpression in hepatocellular carcinoma (HCC)，and to explore the possibility of using trastuzumab in treatment of HCC.Methods 868 surgical samples from patients with primary HCC were detected for their HER-2eu overexpression by DAKO HercepTest，and then the correlatio between HER-2eu overexpression and clinicopathological characteristics were analyzed statistically.Results HER-2eu immuno-labeling was presented in 62 of 868 cases (7.14%).41 cases showed faint perceptible membrane staining in more than 10% of the neoplastic cells (1+).Strong focal or weak diffuse labeling of more than 10% of the neoplastic cells was presented in 20 cases (2+).1 case showed strong diffuse labeling in more than 70% of the cells (3+).In 806 remaining cases，there was no HER-2eu labeling.Adjacent benign liver parenchyma was also uniformly negative.All positive controls stained appropriately.No significant relatio were observed between HER-2eu overexpression and clinicopathological paramete.Conclusion HER-2eu overexpression is detected in 21 (2.42%) of 868 primary HCC cases.Our findings indicates that HER-2eu overexpression is not an important prognostic factor for patients with HCC.There appea to be no role for usage of anti- HER-2eu trastuzumab therapy in patients with HCC. 【Key words】 hepatocellular carcinoma HER-2eu immunohistochemistry 肝细胞癌(hepatocellular carcinoma ，HCC) 是一种常见恶性肿瘤，在我国居恶性肿瘤发病率的第3位，病死率的第2位［1］。因此，寻找敏感而特异的肿瘤标志物对肝癌的早期诊断、治疗方法的合理选择和患者的远期生存率至关重要［2］。研究发现，乳腺癌、卵巢癌、子宫内膜癌、前列腺癌、胃癌等都存在一定比率的HER-2eu基因扩增，抗HER-2eu单克隆抗体trastuzumab可有效治疗高表达HER-2eu的乳腺癌患